Completed PHASE3 NCT01355497

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy

Sponsor: GTx

Conditions Muscle Wasting Non-Small Cell Lung Cancer

Interventions GTx-024 placebo

Updated 7 times since 2017 Last updated: Oct 26, 2020 Started: Jul 31, 2011 Primary completion: May 31, 2013 Completion: Jun 30, 2014

A PHASE3 clinical study on Muscle Wasting and Non-Small Cell Lung Cancer, this trial is completed. The trial is conducted by GTx and has accumulated 7 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Dec 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Dec 2020 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Data source: GTx

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ashland, United States , Birmingham, United States , Burlington, United States , Canfield, United States , Canton, United States , Concord, United States , Decatur, United States , Flat Rock, United States , Goshen, United States , Great Falls, United States and 20 more locations